Publications & Posters

Contributing to and advancing the scientific dialogue

lines_hdr_yellow_noimage

November 2021

Activity of pan-RAF inhibitor DAY101 in a pediatric patient with a recurrent spindle cell sarcoma harboring a novel SNX8-BRAF gene fusion

October 2021

FIRELIGHT: DAY101-102a, a phase 2 subprotocol of DAY101 monotherapy for patients with recurrent, progressive, or refractory solid tumors with an activating BRAF gene fusion

October 2021

Prolonged complete response to the pan-RAF inhibitor DAY101 in a patient with an NRAS-mutated acral lentiginous melanoma

Learn more about the investigational therapies in our pipeline.

lines_PSB_orange